Devices descending from K032766
14 later devices reach Vitek 2 Gram Positive Linezolid through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K212849 | VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) | Biomérieux, Inc. | 2022 | 0 | — |
| +1 | K122547 | Gram Postitve Clindamycin | bioMerieux, Inc. | 2012 | 5 | — |
| +1 | K050075 | Vitek 2 Gram Positive Daptomycin | bioMerieux, Inc. | 2005 | 6 | — |
| +2 | K141149 | Vitek 2 Ast GP Ceftaroline | bioMerieux, Inc. | 2014 | 4 | — |
| +2 | K072695 | Vitek 2 Gram Positive Tigecycline | bioMerieux, Inc. | 2007 | 0 | — |
| +2 | K072668 | Vitek 2 Gram Positive Vancomycin | bioMerieux, Inc. | 2007 | 4 | — |
| +3 | K190616 | VITEK 2 AST-Gram Positive Dalbavancin (<= 0.015 - >= 1 µg/mL) | bioMerieux, Inc. | 2019 | 3 | — |
| +3 | K091126 | Vitek 2 Gram Positive Daptomycin | bioMerieux, Inc. | 2009 | 3 | — |
| +4 | K230864 | VITEK 2 AST-Gram Positive Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP Daptomycin… | bioMerieux, Inc. | 2023 | 1 | — |
| +4 | K212243 | VITEK 2 AST- Gram Positive Telavancin (<=0.015 - >=1 µg/mL) | bioMerieux, Inc. | 2022 | 0 | — |
| +4 | K202396 | VITEK 2 AST-Gram Positive Fosfomycin (<=8 - >=256 ug/mL) | bioMerieux, Inc. | 2021 | 0 | — |
| +4 | K200590 | VITEK 2 AST-Gram Positive Delafloxacin (<=0.015 - >=1 µg/mL) | bioMerieux, Inc. | 2020 | 0 | — |
| +4 | K093076 | Vitek 2 Gram Positive Doxcycline | bioMerieux, Inc. | 2010 | 0 | — |
| +5 | K234000 | VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL) | bioMerieux, Inc. | 2024 | 0 | — |